On the public citation graph
Enhancing Safety Signaling: Integrating Clinical Trials and Post-Marketing Adverse Event Reports
0 signed · 49 inferred · view as graph
Inferred edges come from two machine sources: sweeps of open repository metadata (mostly SSRN and Zenodo), and a bulk OpenAlex citation snapshot. Every row below is labelled with the one it came from. Neither is a complete citation index — absence here is not evidence of absence.
Is this your work? Sign in with ORCID and put your name on the
claims that are yours.
Reference health. See whether every reference in this work resolves to a
known work and none has been retracted — and get a dated CiteStamped
badge you can embed.
What this work says
Outgoing claims: the papers this work cites, builds on, or argues with.
inferredcites →https://doi.org/10.1001/jama.279.15.1200openalex-snapshot
Incidence of Adverse Drug Reactions in Hospitalized Patients
inferredcites →https://doi.org/10.1002/pds.1509openalex-snapshot
Early detection of adverse drug events within population‐based health networks: application of sequential testing methods
inferredcites →https://doi.org/10.1002/pds.3395openalex-snapshot
Evaluation of FDA safety‐related drug label changes in 2010
inferredcites →https://doi.org/10.1002/pds.3805openalex-snapshot
Standardisation of the FAERS database: a systematic approach to manually recoding drug name variants
inferredcites →https://doi.org/10.1002/pds.668openalex-snapshot
A comparison of measures of disproportionality for signal detection in spontaneous reporting systems for adverse drug reactions
inferredcites →https://doi.org/10.1002/phar.1359openalex-snapshot
Cholinesterase Inhibitors and Pisa Syndrome: A Pharmacovigilance Study
inferredcites →https://doi.org/10.1002/sim.2370openalex-snapshot
Improving ecological inference using individual‐level data
inferredcites →https://doi.org/10.1007/bf02479801openalex-snapshot
Bayesian point estimation and prediction
inferredcites →https://doi.org/10.1007/s10208-015-9296-2openalex-snapshot
Random Gradient-Free Minimization of Convex Functions
inferredcites →https://doi.org/10.1007/s40264-013-0108-9openalex-snapshot
A Comparison of the Empirical Performance of Methods for a Risk Identification System
inferredcites →https://doi.org/10.1007/s40264-013-0109-8openalex-snapshot
Replication of the OMOP Experiment in Europe: Evaluating Methods for Risk Identification in Electronic Health Record Databases
inferredcites →https://doi.org/10.1007/s40264-014-0150-2openalex-snapshot
The Weber Effect and the United States Food and Drug Administration’s Adverse Event Reporting System (FAERS): Analysis of Sixty-Two Drugs Approved from 2006 to 2010
inferredcites →https://doi.org/10.1007/s40264-016-0409-xopenalex-snapshot
A Pharmacovigilance Signaling System Based on FDA Regulatory Action and Post-Marketing Adverse Event Reports
inferredcites →https://doi.org/10.1007/s40264-017-0526-1openalex-snapshot
Evaluation of Pre-marketing Factors to Predict Post-marketing Boxed Warnings and Safety Withdrawals
inferredcites →https://doi.org/10.1007/s40264-020-00943-2openalex-snapshot
Combining Social Media and FDA Adverse Event Reporting System to Detect Adverse Drug Reactions
inferredcites →https://doi.org/10.1007/s40264-020-01022-2openalex-snapshot
Frequency and Associated Costs of Anaphylaxis- and Hypersensitivity-Related Adverse Events for Intravenous Iron Products in the USA: An Analysis Using the US Food and Drug Administration Adverse Event Reporting System
inferredcites →https://doi.org/10.1016/j.clinthera.2020.12.011openalex-snapshot
Review of FDA Amendments Act Section 921 Experience in Posting Data-mining Results from the FAERS Database
inferredcites →https://doi.org/10.1016/j.irle.2011.08.003openalex-snapshot
Does competition stimulate drug utilization? The impact of changes in market structure on US drug prices, marketing and utilization
inferredcites →https://doi.org/10.1016/j.jbi.2013.10.008openalex-snapshot
Automatic signal extraction, prioritizing and filtering approaches in detecting post-marketing cardiovascular events associated with targeted cancer drugs from the FDA Adverse Event Reporting System (FAERS)
inferredcites →https://doi.org/10.1016/j.jbi.2015.10.011openalex-snapshot
A research framework for pharmacovigilance in health social media: Identification and evaluation of patient adverse drug event reports
inferredcites →https://doi.org/10.1016/j.therap.2021.12.007openalex-snapshot
Epidemiology and economic burden of “serious” adverse drug reactions: Real-world evidence research based on pharmacovigilance data
inferredcites →https://doi.org/10.1038/sdata.2016.26openalex-snapshot
A curated and standardized adverse drug event resource to accelerate drug safety research
inferredcites →https://doi.org/10.1080/14740338.2017.1323867openalex-snapshot
Empirical estimation of under-reporting in the U.S. Food and Drug Administration Adverse Event Reporting System (FAERS)
inferredcites →https://doi.org/10.1080/14740338.2017.1325463openalex-snapshot
Methods for safety signal detection in healthcare databases: a literature review
inferredcites →https://doi.org/10.1080/14740338.2018.1491547openalex-snapshot
The economic burden of preventable adverse drug reactions: a systematic review of observational studies
inferredcites →https://doi.org/10.1080/14740338.2022.2118712openalex-snapshot
A new paradigm in adverse drug reaction reporting: consolidating the evidence for an intervention to improve reporting
inferredcites →https://doi.org/10.1093/nar/gkv1075openalex-snapshot
The SIDER database of drugs and side effects
inferredcites →https://doi.org/10.1111/j.1467-985x.2010.00673.xopenalex-snapshot
The Use of Propensity Scores to Assess the Generalizability of Results from Randomized Trials
inferredcites →https://doi.org/10.1111/j.2517-6161.1968.tb00741.xopenalex-snapshot
A General Approach to Some Screening and Classification Problems
inferredcites →https://doi.org/10.1111/rssa.12094openalex-snapshot
From Sample Average Treatment Effect to Population Average Treatment Effect on the Treated: Combining Experimental with Observational Studies to Estimate Population Treatment Effects
inferredcites →https://doi.org/10.1126/scitranslmed.3003377openalex-snapshot
Data-Driven Prediction of Drug Effects and Interactions
inferredcites →https://doi.org/10.1136/amiajnl-2011-000096openalex-snapshot
Using information mining of the medical literature to improve drug safety
inferredcites →https://doi.org/10.1136/amiajnl-2011-000116openalex-snapshot
Normalized names for clinical drugs: RxNorm at 6 years
inferredcites →https://doi.org/10.1136/amiajnl-2011-000417openalex-snapshot
Facilitating adverse drug event detection in pharmacovigilance databases using molecular structure similarity: application to rhabdomyolysis
inferredcites →https://doi.org/10.1136/amiajnl-2012-000930openalex-snapshot
Combing signals from spontaneous reports and electronic health records for detection of adverse drug reactions
inferredcites →https://doi.org/10.1136/bmj.329.7456.15openalex-snapshot
Adverse drug reactions as cause of admission to hospital: prospective analysis of 18 820 patients
inferredcites →https://doi.org/10.1186/1472-6947-14-13openalex-snapshot
A pipeline to extract drug-adverse event pairs from multiple data sources
inferredcites →https://doi.org/10.1186/s12913-021-07260-zopenalex-snapshot
Pragmatic pharmacoeconomic analyses by using post-market adverse drug reaction reports: an illustration using infliximab, adalimumab, and the Canada vigilance adverse reaction database
inferredcites →https://doi.org/10.1214/aoms/1177731118openalex-snapshot
Sequential Tests of Statistical Hypotheses
inferredcites →https://doi.org/10.1287/mnsc.2020.3889openalex-snapshot
Enhancing Regulatory Decision Making for Postmarket Drug Safety
inferredcites →https://doi.org/10.1287/mnsc.2021.4137openalex-snapshot
Bayesian Sequential Learning for Clinical Trials of Multiple Correlated Medical Interventions
inferredcites →https://doi.org/10.1287/mnsc.2022.4540openalex-snapshot
Value-Based Clinical Trials: Selecting Recruitment Rates and Trial Lengths in Different Regulatory Contexts
inferredcites →https://doi.org/10.1287/msom.2019.0822openalex-snapshot
Inducing Compliance with Postmarket Studies for Drugs Under FDA’s Accelerated Approval Pathway
inferredcites →https://doi.org/10.1287/opre.2015.1435openalex-snapshot
Active Postmarketing Drug Surveillance for Multiple Adverse Events
inferredcites →https://doi.org/10.2165/00002018-200629050-00003openalex-snapshot
Under-Reporting of Adverse Drug Reactions
inferredcites →https://doi.org/10.2174/1574886310666150729112903openalex-snapshot
The Role of Disproportionality Analysis of Pharmacovigilance Databases in Safety Regulatory Actions: a Systematic Review
inferredcites →https://doi.org/10.2196/27714openalex-snapshot
Quantifying the Severity of Adverse Drug Reactions Using Social Media: Network Analysis
inferredcites →https://doi.org/10.4081/dts.2013.e4openalex-snapshot
Development of a drug safety ePlatform for physicians, pharmacists, and consumers based on post-marketing adverse events
Editorial review for independent work. ICSAC — the Institute for Complexity
Science and Advanced Computing — runs a structured editorial panel for researchers
publishing outside journals, and publishes on CiteStamp rails. Submission is free
and goes through ORCID: icsacinstitute.org/submit.